Segment Information and Geographical information

9 Months Ended

Sep. 30, 2011

Segment Information and Geographical information [Abstract]

Segment Information and Geographical information

Note 11—Segment Information and Geographical information

The Company has two reportable segments: Fibrocell Therapy and Agera. The Fibrocell Therapy segment specializes in the development and commercialization of autologous cellular therapies for soft tissue regeneration. The Agera segment maintains proprietary rights to a scientifically-based advanced line of skincare products. There is no intersegment revenue. The following table provides operating financial information for the continuing operations of the Company’s two reportable segments:

Three Months Ended September 30, 2011

	Segment
	Fibrocell
	Therapy		Agera			Consolidated
Total operating revenue	$	—	$	159,400		$	159,400
Depreciation and amortization expense		63,112		—			63,112
Segment income (loss) from continuing operations	$	6,959,721	$	(37,809	)	$	6,921,912

Nine Months Ended September 30, 2011

	Segment
	Fibrocell
	Therapy			Agera		Consolidated
Total operating revenue	$	—		$	621,310	$	621,310
Depreciation and amortization expense		75,702			—		75,702
Segment income (loss) from continuing operations	$	(20,245,651	)	$	21,852	$	(20,223,799	)

Three Months Ended September 30, 2010

	Segment
	Fibrocell
	Therapy			Agera		Consolidated
Total operating revenue	$	—		$	243,677	$	243,677
Depreciation and amortization expense		2,472			—		2,472
Segment income (loss) from continuing operations	$	(1,816,681	)	$	24,210	$	(1,792,471	)

Nine Months Ended September 30, 2010

	Segment
	Fibrocell
	Therapy			Agera		Consolidated
Total operating revenue	$	—		$	716,809	$	716,809
Depreciation and amortization expense		5,612			—		5,612
Segment income (loss) from continuing operations	$	(8,219,599	)	$	13,722	$	(8,205,877	)

Geographical information concerning the Company’s revenue is as follows:

	Revenue
	Three months ended			Three months ended
	September 30, 2011			September 30, 2010
United States	$	47,454		$	54,367
United Kingdom		123,786			181,931
Other		(11,840	)		7,379
Total	$	159,400		$	243,677

	Revenue
	Nine months ended		Nine months ended
	September 30, 2011		September 30, 2010
United States.	$	142,926	$	176,215
United Kingdom		389,359		472,721
Other		89,025		67,873
Total	$	621,310	$	716,809

During the three months ended September 30, 2011, revenue from one foreign customer and one domestic customer represented 78% and 20% of consolidated revenue, respectively. During the three months ended September 30, 2010, revenue from one foreign customer and one domestic customer represented 75% and 15% of consolidated revenue, respectively.

During the nine months ended September 30, 2011, revenue from one foreign customer and one domestic customer represented 63% and 16% of consolidated revenue, respectively. During the nine months ended September 30, 2010, revenue from one foreign customer and one domestic customer represented 73% and 17% of consolidated revenue, respectively.

As of September 30, 2011 and December 31, 2010, one foreign customer represented 66% and 88%, respectively, of accounts receivable, net.

	Segment
	Fibrocell
Segment assets:	Therapy		Agera		Consolidated
September 30, 2011	$	23,261,939	$	574,079	$	23,836,018
December 31, 2010		7,681,502		596,643		8,278,145